OrthoPediatrics

KIDS

Market cap $444M

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

WARSAW, Ind., Nov. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with two new products launches, the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems. The company now has 31 systems within its OPSB division.

The consensus price target hints at a 41.9% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

WARSAW, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in three upcoming investor conferences.

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants David Bailey - President, CEO & Director Fred Hite - CFO, Principal Financial & Accounting Officer, COO and Director Conference Call Participants Philip Taylor - Gilmartin Group LLC David Turkaly - Citizens JMP Securities, LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to the OrthoPediatrics Corporation Third Quarter 2025 Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.18 per share a year ago.

WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025.

WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company's 6th FDA approval in 2025.

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.